| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.47 | 16.7% | 26.7% |
| Total Income | 1.47 | 16.7% | 26.7% |
| Expenditure | 14.28 | 6.8% | 13.8% |
| PBT | -11.69 | 16.0% | 163.3% |
| Net Profit | -11.69 | 16.0% | 163.3% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.08 | 52.9% | 0.0% |
Lucid Diagnostics Reports Q2 2026 Financial Results and Business Update
13 Aug 2026 · 13 Aug, 5:59 pm
Summary
Lucid Diagnostics reported second quarter 2026 revenue of $1.5 million, primarily from its EsoGuard product, and processed 2,770 tests. The company secured a significant commercial coverage policy from Concert and developed a cost-effectiveness model for EsoGuard. Despite a GAAP net loss of $14.7 million ($0.08 per share), the non-GAAP adjusted loss was $10.9 million ($0.06 per share), with cash reserves standing at $33.4 million.
Key Highlights
- 1
Lucid Diagnostics recognized $1.5 million in EsoGuard revenue for the second quarter of 2026.
- 2
The company processed 2,770 EsoGuard® Esophageal DNA Tests in Q2 2026.
- 3
Lucid Diagnostics secured a commercial coverage policy for EsoGuard from Concert, which has been adopted by multiple client health plans.
- 4
A health economic cost-effectiveness model for EsoGuard screening demonstrated improved clinical outcomes and cost-effectiveness.
- 5
GAAP net loss attributable to common stockholders was approximately $14.7 million, or $(0.08) per common share for Q2 2026.
- 6
Non-GAAP adjusted loss for Q2 2026 was approximately $10.9 million, or $(0.06) per common share.
- 7
The company had $33.4 million in cash and cash equivalents as of June 30, 2026.
Management Comments
Lishan Aklog
Lucid’s commercial momentum strengthened throughout the second quarter and in recent weeks. We continue to advance multiple commercial priorities while awaiting a positive draft Medicare coverage policy for EsoGuard. We secured positive commercial coverage policies, accelerated engagement with the VA and major health systems, and demonstrated the long-term economic value of EsoGuard testing. Progress across these initiatives positions Lucid to capitalize on EsoGuard’s significant clinical and commercial opportunity, while increasing the company’s visibility and thereby expanding opportunities for broader strategic engagement.
Informational and educational content only. Not investment advice.